Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells. However, these agents, now approved for over 15 types of cancers and for both early-stage and metastatic disease, are capable of causing inflammation in any organ system of the body that can lead to organ damage, dysfunction, and even death in rare cases. Some patients may suffer acute and treatable complications like joint pain, but some may have irreversible complications like hypothyroidism th

Trial Details

NCT ID
NCT07555210
Phase
NA
Sponsor
Jessica Mezzanotte Sharpe
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Dual-Energy X-ray Absorptiometry (DXA)
  • High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
Locations (sample)
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Patients planning to start or within the first four weeks of treatment with anti-PD-1 immune checkpoint inhibitor therapy either alone or in combin…
  • Life expectancy of at least 12 months per the discretion of the treating physician.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →